Published: August 2026 | Category: Autoimmune & Respiratory Research
Reviewed Evidence
Reviewed Study 1: A Placebo-Controlled, Randomized Trial of Mesenchymal Stem Cells in COPD
Authors: Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP
Publication & Date: Chest. 2013;143(6):1590-1598.
DOI / Link: https://doi.org/10.1378/chest.12-2094 | PubMed
Reviewed Study 2: Effect of Mesenchymal Stromal Cell Infusions on Lung Function in COPD Patients With High CRP Levels
Authors: Weiss DJ, Segal K, Casaburi R, Hayes J, Tashkin DP
Publication & Date: Respiratory Research. 2021;22:142.
DOI / Link: https://doi.org/10.1186/s12931-021-01734-8 | PubMed
Reviewed Study 3: Safety, Immunological Effects and Clinical Response in a Phase I Trial of Umbilical Cord Mesenchymal Stromal Cells in Patients With Treatment Refractory SLE
Authors: Kamen DL, Wallace C, Li Z, et al.
Publication & Date: Lupus Science & Medicine. 2022;9(1):e000704.
DOI / Link: https://doi.org/10.1136/lupus-2022-000704 | PubMed
Reviewed Study 4: A Randomised Double-Blind, Placebo-Controlled Trial of Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cell for Lupus Nephritis
Authors: Deng D, Zhang P, Guo Y, Lim TO
Publication & Date: Annals of the Rheumatic Diseases. 2017;76(8):1436-1439.
DOI / Link: https://doi.org/10.1136/annrheumdis-2017-211073 | PubMed
Scientific Review By: Michael Healey, M.Ed., C.A.S.
Executive Summary & Key Takeaways
- Primary Objective: Evaluate whether mesenchymal stromal cells (MSCs) reduce systemic inflammation in COPD and lupus and produce meaningful clinical benefits beyond placebo or standard treatment.
- Cell Types Evaluated: Allogeneic bone-marrow-derived MSCs were used in the COPD trial, while the lupus studies evaluated allogeneic umbilical-cord-derived MSCs.
- Key Finding: MSCs produced biological and immune-modulating signals, including changes involving CRP and B-cell/TGF-β signaling. Controlled trials, however, did not establish overall clinical benefit in COPD or an additional remission benefit in lupus nephritis.
- Safety and Tolerability: MSC infusions were generally well tolerated in these small studies, but long-term safety remains uncertain. The evidence does not show that MSCs reduce oxygen dependence in COPD or replace corticosteroids or other standard therapies.
Study Overview & Clinical Objectives
For patients researching stem cell therapy for COPD inflammation, this independent review evaluates whether mesenchymal stromal cells (MSCs) measurably modulate inflammation in chronic obstructive pulmonary disease (COPD) and systemic lupus erythematosus (SLE), and whether those biological effects translate into meaningful patient benefits. Four publications were evaluated. The COPD evidence includes a 62-patient, multicenter, randomized, double-blind, placebo-controlled Phase I/II trial and a later post hoc analysis of 29 participants from that same trial who had elevated C-reactive protein (CRP). The lupus evidence includes a six-patient, open-label Phase I immunology study and an 18-patient, randomized, double-blind, placebo-controlled trial involving patients with class III or IV lupus nephritis. Together, the publications describe three participant cohorts. Because the studies differed in disease, MSC source, dose, treatment schedule, background therapy, endpoints, and follow-up, their findings could not be pooled or interpreted as evidence of a shared clinical effect. Greater emphasis was placed on controlled comparisons between groups than on biomarker changes, correlations, post hoc subgroup findings, or response rates from uncontrolled studies. Biological activity was assessed separately from clinically meaningful outcomes such as lung function, exercise capacity, exacerbations, disease activity, renal remission, treatment exposure, and adverse events.
Biological Mechanism & Science
MSCs are better understood as transient, environmentally responsive signaling cells than as cells that replace damaged lung, kidney, or immune tissue. After exposure to inflammatory signals, MSCs may release soluble mediators and extracellular vesicles that influence macrophages, neutrophils, T cells, B cells, and regulatory immune networks. The response depends on cell source, manufacturing, dose, route, and the recipient's inflammatory environment. Human findings support possible biological activity, but remain limited. In COPD, the Weiss trial measured circulating CRP, and its later reanalysis used elevated baseline CRP to identify a potentially responsive inflammatory phenotype. However, the analysis did not establish that changes in inflammation caused improvements in lung function or exercise capacity. In refractory SLE, Kamen and colleagues observed shifts in B-cell populations and increased GARP/TGF-β complexes that correlated with disease activity. With only six participants and no control group, these associations may also reflect background immunosuppression, natural disease fluctuation, or regression to the mean. COPD and SLE have distinct underlying biological mechanisms. A shared ability to alter immune signaling does not establish equivalent efficacy, and biomarker or cellular changes alone cannot demonstrate improved breathing, reduced supplemental-oxygen use, lupus remission, steroid independence, organ recovery, or durable disease modification. Delivery was intravenous in the reviewed studies. The COPD trial used four monthly doses of 100 million bone-marrow-derived MSCs, whereas Kamen used a single dose of 1 × 10⁶ umbilical-cord-derived MSCs/kg. Cell viability after thawing and validated measures of potency were not reported consistently enough to support direct comparisons between products.
Key Findings & Patient Outcomes
In the overall randomized COPD trial, MSCs were generally well tolerated but did not significantly improve lung function, six-minute walk distance, shortness of breath, health status, or exacerbation rates compared with placebo. In a post hoc subgroup of participants with baseline CRP levels of 4 mg/L or higher, changes in FEV₁ and six-minute walk distance favored MSC treatment. However, these findings are preliminary because the subgroup was small, the CRP threshold was selected after the data were examined, multiple thresholds and outcomes were tested, and changes in CRP did not correspond with functional improvements. MSCs also did not improve patient-reported outcomes or exacerbation rates in this subgroup. In the Kamen lupus study, five of six participants met the criteria for an SRI-4 response. However, the study was small and did not include a control group, so the results cannot establish that MSC treatment caused the improvement. The placebo-controlled lupus nephritis trial by Deng and colleagues provides stronger evidence of effectiveness. Renal remission occurred in 9 of 12 MSC recipients, or 75 percent, compared with 5 of 6 placebo recipients, or 83 percent. Both groups also received intensive standard immunosuppressive treatment. The trial therefore did not show that adding MSCs improved remission rates beyond standard therapy. None of the reviewed studies showed that MSCs reduced oxygen dependence or could replace corticosteroids or other standard treatments.
Clinical Data Summary
| Clinical Metric | Trial Specification |
|---|---|
| Study Type | Comparative review of four publications describing three participant cohorts, including two randomized, double-blind, placebo-controlled trials |
| Participant Count | COPD RCT N=62; elevated-CRP reanalysis n=29 from the same trial; Kamen SLE N=6; Deng lupus nephritis N=18 |
| Cell Type and Delivery | Allogeneic bone-marrow MSCs in COPD; allogeneic umbilical-cord MSCs in SLE; intravenous delivery |
| Follow-Up | Varied by study; the COPD randomized trial included two-year follow-up, and Kamen followed participants for 24 weeks |
| Primary Outcomes | Pulmonary function, six-minute walk distance, exacerbations, CRP, SLE disease activity, renal remission, and safety |
| Evidence Summary | No established overall COPD efficacy, added lupus-nephritis remission benefit, reduction in oxygen dependence, or steroid replacement |
Stemedix Clinical Context
From a clinical perspective, the evidence supports careful investigation, not treatment certainty. For patients researching stem cell therapy for COPD inflammation, the direct answer is that MSCs may alter inflammatory signaling, but controlled trials have not shown that they reduce oxygen requirements. The encouraging high-CRP COPD signal arose from a small post hoc analysis and requires confirmation in a prospectively defined, adequately powered trial. In lupus, early immune and clinical signals have not been confirmed as an added benefit in the available randomized lupus-nephritis trial. The reviewed interventions are experimental and product-specific. Results from one MSC source, manufacturing process, dose, or patient population should not be generalized to another. The small study populations cannot establish uncommon or delayed harms, and short-term infusion tolerability is not equivalent to long-term safety. Patients should not discontinue oxygen, inhaled therapies, corticosteroids, immunosuppressants, biologics, or other prescribed treatments based on these findings. Future trials should prospectively define inflammatory phenotypes, standardize product characterization and potency measures, and prioritize outcomes that matter to patients, including exacerbations, hospitalizations, pulmonary function, exercise capacity, oxygen requirements, steroid exposure, lupus activity, renal outcomes, quality of life, and durable adverse events. Patients considering MSC therapy should discuss the evidence with a qualified physician who can distinguish investigational findings from established care and determine whether an appropriate regulated clinical trial is available.
Frequently Asked Questions
How do MSCs reduce inflammation in COPD and lupus?
Research into stem cell therapy for COPD inflammation suggests that MSCs may release signaling molecules that influence immune cells and help regulate inflammatory responses. However, human studies have not yet established that these biological effects consistently improve symptoms or disease outcomes.
Can MSC therapy improve lung function or reduce oxygen use in people with COPD?
The reviewed COPD studies did not show significant improvements in lung function or exercise capacity. They also did not demonstrate that MSC therapy reduces or eliminates the need for supplemental oxygen.
Can MSC therapy replace standard treatment for lupus?
No. The reviewed studies did not establish MSC therapy as a replacement for corticosteroids, immunosuppressive medications, or other standard lupus treatments. Although some early findings suggest possible effects on immune activity and disease measures, larger controlled trials are needed to determine whether MSCs provide additional clinical benefit.
Regulatory Disclaimer
This review is provided by Stemedix for educational and informational purposes only and represents an academic commentary on published literature. The featured studies evaluate experimental procedures. Regenerative cell therapies discussed are non-FDA-approved treatments unless explicitly stated otherwise. Consult a board-certified physician before making medical decisions.
References
- Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest. 2013;143(6):1590-1598. doi:10.1378/chest.12-2094. https://pubmed.ncbi.nlm.nih.gov/23172272/
- Weiss DJ, Segal K, Casaburi R, Hayes J, Tashkin DP. Effect of mesenchymal stromal cell infusions on lung function in COPD patients with high CRP levels. Respir Res. 2021;22:142. doi:10.1186/s12931-021-01734-8. https://pubmed.ncbi.nlm.nih.gov/33964910/
- Kamen DL, Wallace C, Li Z, et al. Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE. Lupus Sci Med. 2022;9(1):e000704. doi:10.1136/lupus-2022-000704. https://pubmed.ncbi.nlm.nih.gov/35820718/
- Deng D, Zhang P, Guo Y, Lim TO. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis. 2017;76(8):1436-1439. doi:10.1136/annrheumdis-2017-211073. https://pubmed.ncbi.nlm.nih.gov/28478399/